Tibet Aim Pharm Inc

Yiming Pharmaceutical released its 2026 interim report. The company's total operating revenue was 360 million yuan, net profit attributable to the parent was 66.6797 million yuan, and net cash inflow from operating activities was 174 million yuan. The company's latest asset-liability ratio was 27.82%, up 3.78 percentage points from the previous quarter and up 4.50 percentage points from the same period last year. Gross margin was 82.02%, down 0.46 percentage points from the previous quarter. ROE was 7.72%, and diluted earnings per share was 0.36 yuan. Total asset turnover was 0.32 times, and inventory turnover was 1.14 times, down 14.13% from the same period last year. The number of shareholders was 15,000, and the top ten shareholders held 37.91% of total share capital.

Yiming Pharmaceutical announced that the company has completed its first buyback of 130,000 shares, representing 0.07% of total share capital, with a total buyback amount of 2.23 million yuan and a buyback price range of 17.79 yuan to 17.91 yuan per share. In the first quarter of 2026, Yiming Pharmaceutical achieved revenue of 183 million yuan and net profit attributable to the parent company of 19.65 million yuan.

Yiming Pharmaceutical repurchased 125,000 shares of the company for the first time through a special securities account for share repurchases using centralized bidding, accounting for 0.07% of the company's current total share capital. The repurchase price ranged from 17.79 yuan to 17.91 yuan per share, with a total transaction amount of approximately 2.23 million yuan. According to a previous announcement, Yiming Pharmaceutical's total repurchase funds for this round range from 35 million yuan to 70 million yuan, with a repurchase price not exceeding 25.74 yuan per share. The repurchased shares are intended for equity incentives or an employee stock ownership plan.